BIRMINGHAM, Ala., April 3, 2023 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) will hold its annual meeting of stockholders at 11:00 a.m. CDT, on Thursday, May 4, 2023. The meeting will be held at the Company's Home Office located at 9001 Liberty Parkway in Birmingham, Alabama.
Stockholders planning to attend the meeting will be asked to present valid picture identification, such as a driver's license or passport, and proof of stock ownership. Reporters planning to attend are requested to pre-register with Casey Winger by calling 205-970-5912 or emailing This email address is being protected from spambots. You need JavaScript enabled to view it. no later than Friday, April 28, 2023.
For Encompass Health stockholders not able to attend the meeting and other interested parties, a live audio webcast can be accessed at https://investor.encompasshealth.com. Those interested may replay the audio webcast through an archived link on the same website following the meeting.
About Encompass Health
Encompass Health (NYSE: EHC) is the largest owner and operator of rehabilitation hospitals in the United States. With a national footprint that includes 156 hospitals in 37 states and Puerto Rico, the Company provides high-quality, compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and innovative treatments to maximize recovery. Encompass Health is ranked as one of Fortune's 100 Best Companies to Work For and Modern Healthcare's Best Places to Work in Healthcare. For more information, visit encompasshealth.com, or follow us on our newsroom, Twitter, Instagram and Facebook.
Media Contact:
Casey Winger | 205-970-5912
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations Contact:
Mark Miller | 205-970-5860
This email address is being protected from spambots. You need JavaScript enabled to view it.

| Last Trade: | US$113.85 |
| Daily Change: | -2.96 -2.53 |
| Daily Volume: | 2,048,053 |
| Market Cap: | US$11.470B |
October 29, 2025 August 07, 2025 August 04, 2025 June 18, 2025 | |

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load